StockNews.com assumed coverage on shares of IGC Pharma (NYSEAMERICAN:IGC – Free Report) in a report published on Monday. The brokerage issued a sell rating on the construction company’s stock.
IGC Pharma Stock Performance
IGC opened at $0.52 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.86 and a current ratio of 1.85. IGC Pharma has a fifty-two week low of $0.25 and a fifty-two week high of $0.91. The firm has a market cap of $34.74 million, a P/E ratio of -2.00 and a beta of 1.63.
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The construction company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.20 million during the quarter. IGC Pharma had a negative return on equity of 110.37% and a negative net margin of 1,163.24%.
Institutional Inflows and Outflows
IGC Pharma Company Profile
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.
Featured Stories
- Five stocks we like better than IGC Pharma
- 3 Monster Growth Stocks to Buy Now
- Roblox: The Bottom Just Fell Out of the Metaverse
- The How And Why of Investing in Oil Stocks
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- How Can Investors Benefit From After-Hours Trading
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
